Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol

Roberts, Matthew J.; Yaxley, John; Coughlin, Geoffrey; Gianduzzo, Troy; Esler, Rachel; Dunglison, Nigel; Chambers, Suzanne K.; Medcraft, Robyn J; Chow, Clement W. K.; Schirra, Horst Joachim; Richards, Renée S.; Kienzle, N.; Lu, Macy; Brereton, Ian M.; Samaratunga, Hemamali; Perry-Keene, Joanna; Payton, Diane; Oyama, C; Doi, Suhail A.R.; Lavin, Martin F.; Gardiner, Robert A.

doi:10.1016/j.cct.2016.06.014

Cited by 6 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 28 , 30 Thus, patients with lower grade tumors may be amenable to SP-mediated in vitro or magnetic resonance spectroscopic imaging (MRSI)-mediated in vivo assessment or monitoring as a potential substitute for repeat biopsy in active surveillance. 28 , 31 …”

Section: Discussionmentioning

confidence: 99%

Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: A preliminary investigation

Roberts

Richards

Chow

et al. 2017

Prostate International

Self Cite

View full text Add to dashboard Cite

BackgroundDiagnosis and monitoring of localized prostate cancer requires discovery and validation of noninvasive biomarkers. Nuclear magnetic resonance (NMR)-based metabolomics of seminal plasma reportedly improves diagnostic accuracy, but requires validation in a high-risk clinical cohort.Materials and methodsSeminal plasma samples of 151 men being investigated for prostate cancer were analyzed with 1H-NMR spectroscopy. After adjustment for buffer (add-to-subtract) and endogenous enzyme influence on metabolites, metabolite profiling was performed with multivariate statistical analysis (principal components analysis, partial least squares) and targeted quantitation.ResultsSeminal plasma metabolites best predicted low- and intermediate-risk prostate cancer with differences observed between these groups and benign samples. Lipids/lipoproteins dominated spectra of high grade samples with less metabolite contributions. Overall prostate cancer prediction using previously described metabolites was not validated.ConclusionMetabolomics of seminal plasma in vitro may assist urologists with diagnosis and monitoring of either low or intermediate grade prostate cancer. Less clinical benefit may be observed for high-risk patients. Further investigation in active surveillance cohorts, and/or in combination with in vivo magnetic resonance spectroscopic imaging may further optimize localized prostate cancer outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: A preliminary investigation

Roberts

Richards

Chow

et al. 2017

Prostate International

Self Cite

View full text Add to dashboard Cite

show abstract

“…The chemo-preventive effect of statin in prostate cancer remains to be investigated [198,199]. An RCT was designed to assess the potential synergies of metformin and atorvastatin for prostate cancer but has been terminated due to the low incidence of eligible patients [200].…”

Section: Prostate Cancermentioning

confidence: 99%

Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer

et al. 2022

View full text Add to dashboard Cite

The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, are administered as first-line therapy for hypercholesterolemia, both as primary and secondary prevention. Besides the lipid-lowering effect, statins have been suggested to inhibit the development of cardiovascular disease through anti-inflammatory, antioxidant, vascular endothelial function-improving, plaque-stabilizing, and platelet aggregation-inhibiting effects. The preventive effect of statins on atherothrombotic stroke has been well established, but statins can influence other cerebrovascular diseases. This suggests that statins have many neuroprotective effects in addition to lowering cholesterol. Furthermore, research suggests that statins cause pro-apoptotic, growth-inhibitory, and pro-differentiation effects in various malignancies. Preclinical and clinical evidence suggests that statins inhibit tumor growth and induce apoptosis in specific cancer cell types. The pleiotropic effects of statins on cardiovascular and cerebrovascular diseases have been well established; however, the effects of statins on cancer patients have not been fully elucidated and are still controversial. This review discusses the recent evidence on the effects of statins on cardiovascular and cerebrovascular diseases and cancer. Additionally, this study describes the pharmacological action of statins, focusing on the aspect of ‘beyond lipid-lowering’.

show abstract

“…[11][12][13] More importantly, during the termination step various small molecules are produced, which induce oncogenic mutations and activate oncogenic pathways, promoting carcinogenesis. 14,15 Some studies have reported that a high-fat diet can result in increased estrogen concentrations in the serum, potentially through increased de novo synthesis. 16 Some other studies elucidated that the histopathological markers -estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu) expression) are frequently associated with breast cancer.…”

Section: 8mentioning

confidence: 99%

A Retrospective Case-Control Study of Lipid Profiles in Carcinoma Breast in Comparison with Normal Controls

Yalagachin

Praveena²

2021

Med. J. Shree Birendra Hosp.

View full text Add to dashboard Cite

Introduction: Breast cancer is the second most common cancer in the world. One of the reasons for its increasing prevalence, especially in younger women has been attributed to lifestyle changes. All these factors also have a strong association with lipid metabolism. More evidence is coming forward to emphasise the protective effect of lifestyle modification to lower lipid levels and thus decreasing the risk of breast cancer. Methods: It is a retrospective, case control study. The patients with carcinoma breast and normal controls were taken as subjects. The data for this study includes clinical profile and lipid profile measured in early morning fasting sample of the subjects. The patients of carcinoma breast, normal control aged > 18 years were included, while patients with diabetes, thyroid disorders, on treatment for hyper-lipidaemia, dieting or anorexic, pregnant patients were excluded. Results: There was no statistically significant differences in age (p = 0.920) and BMI (p = 0.137) between study and normal control group. Total Cholesterol (TC) and Triglycerides (TG) levels were significantly elevated (p = 0.009 and 0.000 respectively) in carcinoma breast group compared to normal controls, however no significant differences (p > 0.05) observed in the levels of HDL-C, LDL-C. Conclusions: There is a significant alteration in lipid metabolism in carcinoma breast patients in comparison to normal controls.

show abstract

Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol

Cited by 6 publications

References 37 publications

Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: A preliminary investigation

Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: A preliminary investigation

Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer

A Retrospective Case-Control Study of Lipid Profiles in Carcinoma Breast in Comparison with Normal Controls

Contact Info

Product

Resources

About